BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 33273018)

  • 1. Use of bevacizumab before or after radiotherapy increases the risk of fistula formation in patients with cervical cancer.
    Kim N; Choi SH; Chang JS; Kim YT; Kim SW; Kim GM; Kim YB
    Int J Gynecol Cancer; 2021 Jan; 31(1):59-65. PubMed ID: 33273018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased genitourinary fistula rate after bevacizumab in recurrent cervical cancer patients initially treated with definitive radiochemotherapy and image-guided adaptive brachytherapy.
    Sturdza A; Hofmann S; Kranawetter M; Polterauer S; Grimm C; Krainer M; Kirisits C; Pötter R; Reinthaller A; Schwameis R
    Strahlenther Onkol; 2017 Dec; 193(12):1056-1065. PubMed ID: 28721510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.
    Redondo A; Colombo N; McCormack M; Dreosti L; Nogueira-Rodrigues A; Scambia G; Lorusso D; Joly F; Schenker M; Ruff P; Estevez-Diz M; Irahara N; Donica M; Gonzalez-Martín A
    Gynecol Oncol; 2020 Oct; 159(1):142-149. PubMed ID: 32763109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of addition of bevacizumab to chemoradiotherapy in newly diagnosed stage IVB cervical cancer: a single institution experience in Korea.
    Youn SH; Kim YJ; Seo SS; Kang S; Lim MC; Chang HK; Park SY; Kim JY
    Int J Gynecol Cancer; 2020 Jun; 30(6):764-771. PubMed ID: 32276937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study.
    Chung YL; Jian JJ; Cheng SH; Hsieh CI; Tan TD; Chang HJ; Hung CF; Horng CF; Soong T; Tsou MH
    Gynecol Oncol; 2005 Apr; 97(1):126-35. PubMed ID: 15790448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of fistula occurrence in patients with cervical cancer treated with bevacizumab: data from real-world clinical practice.
    Sugiyama T; Katsumata N; Toita T; Ura M; Shimizu A; Kamijima S; Aoki D
    Int J Clin Oncol; 2022 Sep; 27(9):1517-1528. PubMed ID: 35760943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal/genitourinary perforation and fistula formation with or without bevacizumab in patients with previously irradiated recurrent cervical cancer: a Korean multicenter retrospective study of the Gynecologic Oncology Research Investigators Collaboration (GORILLA) group (GORILLA-1001).
    Hwang WY; Chang SJ; Kim HS; Kim NK; Kim TH; Kim Y; Kong TW; Lee EJ; Park SJ; Shim SH; Son JH; Suh DH; Yang EJ
    BMC Cancer; 2022 Jun; 22(1):603. PubMed ID: 35655188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective multi-institutional study of definitive radiotherapy with high-dose-rate intracavitary brachytherapy in patients with nonbulky (<4-cm) stage I and II uterine cervical cancer (JAROG0401/JROSG04-2).
    Toita T; Kato S; Niibe Y; Ohno T; Kazumoto T; Kodaira T; Kataoka M; Shikama N; Kenjo M; Tokumaru S; Yamauchi C; Suzuki O; Sakurai H; Numasaki H; Teshima T; Oguchi M; Kagami Y; Nakano T; Hiraoka M; Mitsuhashi N
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):e49-56. PubMed ID: 21470794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-invasive stereotactic ablative boost in patients with locally advanced cervical cancer.
    Dalwadi S; Echeverria A; Jhaveri P; Bui T; Waheed N; Tran D; Bonnen M; Ludwig M
    Int J Gynecol Cancer; 2020 Nov; 30(11):1684-1688. PubMed ID: 32636273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulsed low dose rate brachytherapy for uterine cervix carcinoma.
    Rogers CL; Freel JH; Speiser BL
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(1):95-100. PubMed ID: 9989519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of morbidity after external radiotherapy and intracavitary brachytherapy in 771 patients with carcinoma of the uterine cervix or endometrium.
    Yalman D; Arican A; Ozsaran Z; Celik OK; Yürüt V; Esassolak M; Haydaroglu A
    Eur J Gynaecol Oncol; 2002; 23(1):58-62. PubMed ID: 11876395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer.
    Contreras J; Srivastava A; Chundury A; Schwarz JK; Markovina S; Thaker PH; Massad LS; Mutch DG; Powell MA; Grigsby PW; Lin AJ
    Int J Gynecol Cancer; 2020 Aug; 30(8):1157-1161. PubMed ID: 32527770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transperineal low-dose rate iridium-192 interstitial brachytherapy in cervical carcinoma stage IIB.
    Budrukkar AN; Shrivastava SK; Jalali R; Agarwal JP; Deshpande DD; Nehru RM; Dinshaw KA
    Strahlenther Onkol; 2001 Oct; 177(10):517-24. PubMed ID: 11680016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients.
    Koh V; Choo BA; Lee KM; Tan TH; Low JH; Ng SY; Ilancheran A; Shen L; Tang J
    Brachytherapy; 2017; 16(1):126-132. PubMed ID: 27816539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes following conventional external beam radiotherapy boost in Japanese patients with cervical cancer who are ineligible for intracavitary brachytherapy.
    Ito K; Shimizuguchi T; Karasawa K
    Jpn J Clin Oncol; 2019 Mar; 49(3):270-275. PubMed ID: 30576504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination external beam radiotherapy and high-dose-rate intracavitary brachytherapy for uterine cervical cancer: analysis of dose and fractionation schedule.
    Toita T; Kakinohana Y; Ogawa K; Adachi G; Moromizato H; Nagai Y; Maehama T; Sakumoto K; Kanazawa K; Murayama S
    Int J Radiat Oncol Biol Phys; 2003 Aug; 56(5):1344-53. PubMed ID: 12873679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Treatment of Pelvic Locoregional Recurrence of Cervical Cancer After Radical Surgery With Intensity-Modulated Radiation Therapy Compared With Conventional Radiotherapy: A Retrospective Study.
    Yin YJ; Li HQ; Sheng XG; Du XL; Wang C; Lu CH; Pan CX
    Int J Gynecol Cancer; 2015 Jul; 25(6):1058-65. PubMed ID: 25647254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of severe gastrointestinal toxicity after external beam radiotherapy and interstitial brachytherapy for advanced or recurrent gynecologic malignancies.
    Kasibhatla M; Clough RW; Montana GS; Oleson JR; Light K; Steffey BA; Jones EL
    Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):398-403. PubMed ID: 16542793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effectiveness and safety of image-based, transperineal combined intracavitary and interstitial brachytherapy in treatment of locally advanced cervical cancer.
    Tiwari R; Narayanan GS; Narayanan S; Suresh Kumar P
    Brachytherapy; 2020; 19(1):73-80. PubMed ID: 31813739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unique role of proximal rectal dose in late rectal complications for patients with cervical cancer undergoing high-dose-rate intracavitary brachytherapy.
    Cheng JC; Peng LC; Chen YH; Huang DY; Wu JK; Jian JJ
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):1010-8. PubMed ID: 14575832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.